Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2001-5-28
pubmed:abstractText
The cyclooxygenase 2 (COX-2) and ErbB/HER pathways are important modulators of cancer cell growth. We sought to determine the effects of treatment with a specific COX-2 inhibitor and/or a monoclonal antibody against the ErbB receptor subtype HER-2/neu on carcinoma cell growth.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2, http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2 Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Isoenzymes, http://linkedlifedata.com/resource/pubmed/chemical/Membrane Proteins, http://linkedlifedata.com/resource/pubmed/chemical/PTGS2 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandin-Endoperoxide Synthases, http://linkedlifedata.com/resource/pubmed/chemical/Pyrazoles, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2, http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides, http://linkedlifedata.com/resource/pubmed/chemical/celecoxib, http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0016-5085
pubmed:author
pubmed:issnType
Print
pubmed:volume
120
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1713-9
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:11375952-Animals, pubmed-meshheading:11375952-Antibodies, Monoclonal, pubmed-meshheading:11375952-Antibodies, Monoclonal, Humanized, pubmed-meshheading:11375952-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:11375952-Colorectal Neoplasms, pubmed-meshheading:11375952-Cyclooxygenase 2, pubmed-meshheading:11375952-Cyclooxygenase 2 Inhibitors, pubmed-meshheading:11375952-Cyclooxygenase Inhibitors, pubmed-meshheading:11375952-Female, pubmed-meshheading:11375952-Humans, pubmed-meshheading:11375952-Isoenzymes, pubmed-meshheading:11375952-Membrane Proteins, pubmed-meshheading:11375952-Mice, pubmed-meshheading:11375952-Neoplasm Transplantation, pubmed-meshheading:11375952-Prostaglandin-Endoperoxide Synthases, pubmed-meshheading:11375952-Pyrazoles, pubmed-meshheading:11375952-Receptor, erbB-2, pubmed-meshheading:11375952-Sulfonamides, pubmed-meshheading:11375952-Transplantation, Heterologous, pubmed-meshheading:11375952-Tumor Cells, Cultured
pubmed:year
2001
pubmed:articleTitle
Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth.
pubmed:affiliation
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2279, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't